Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Perioperative Pembrolizumab for MSI-H/dMMR Colorectal Cancer
In this phase II trial of patients with localized dMMR/MSI colorectal cancer, perioperative pembrolizumab achieved a pathologic complete response rate of 53%. Treatment was feasibl
New Reference: Ivonescimab with Chemotherapy for Advanced Squamous NSCLC
In this phase 3 trial for advanced squamous non-small-cell lung cancer, ivonescimab plus chemotherapy significantly improved overall survival compared to tislelizumab plus chemothe
New Indication: Duvelisib for Peripheral T-Cell Lymphoma
This phase II PRIMO trial demonstrated that duvelisib monotherapy has significant clinical activity in heavily pretreated relapsed/refractory peripheral T-cell lymphoma, with an ov
New Protocol: Datopotamab deruxtecan with Durvalumab for Triple-Negative Breast Cancer
This phase Ib/II BEGONIA study evaluated first-line datopotamab deruxtecan combined with durvalumab in unresectable locally advanced or metastatic triple-negative breast cancer. Th
New Drug: Daraxonrasib for Previously Treated Pancreatic Cancer
In this phase 3 randomized trial in patients with previously treated metastatic pancreatic ductal adenocarcinoma, treatment with daraxonrasib significantly improved overall surviva
New Reference: Carboplatin Addition to (Neo)Adjuvant Therapy in Triple-Negative Breast Cancer
In this phase 3 trial of early-stage triple-negative breast cancer, adding carboplatin to taxanes significantly improved 5-year event-free survival with a hazard ratio of 0.67. The
New Reference: Perioperative Apalutamide in High-Risk Localized Prostate Cancer
In this phase 3 trial in patients with high-risk localized or locally advanced prostate cancer, perioperative treatment with ADT plus apalutamide significantly improved pathologica
New Protocol: Zanidatamab with Chemotherapy for Metastatic HER2-Positive Gastroesophageal Cancer
In a phase 3 open-label randomized trial of previously untreated HER2-positive advanced gastroesophageal adenocarcinoma, zanidatamab plus chemotherapy both with and without tisleli
New Reference: Fixed-Duration Venetoclax- Obinutuzumab for Untreated CLL
The CRISTALLO phase 3 trial showed that fixed-duration venetoclax-obinutuzumab significantly improved rates of undetectable minimal residual disease in peripheral blood at month 15
